Five Prime Therapeutics Inc

Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The company's key product candidates are: FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 that it is studying in a clinical trial in multiple cancers; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that the company is studying in a clinical trial in multiple cancers; and Cabiralizumab (FPA008) is an antibody that the company and its partner Bristol-Myers Squibb Company, or BMS, are studying in clinical trials in multiple cancers in combination with BMS's PD-1 immune checkpoint inhibitor, Opdivo? (nivolumab).
  • TickerFPRX
  • ISINUS33830X1046
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Jun 01 2021 6:51AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Wedbush Monthly Check-Up: June 2021

Wedbush Research

Wedbush Morning Call - May 03 2021 6:54AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 01 2021 6:51AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Wedbush Monthly Check-Up: June 2021

Wedbush Research

Wedbush Morning Call - May 03 2021 6:54AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ResearchPool Subscriptions

Get the most out of your insights

Get in touch